SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (491)5/21/2012 1:12:16 PM
From: ghmm  Read Replies (1) of 508
 
I found the imbalance in acute exacerbation very interesting especially given no meaningful difference in FVC. I would suspect this led to the mortal imbalance as well (but I didn't see it mentioned in the paper). I wonder if azathioprine and/or prednisone triggered this in some patients. I've seen theories on these drugs being beneficial in some patients and yet harmful in others (if there are really different underlying diseases that would make a lot of sense).

The NAC arm is continuing and past studies with NAC have shown some promise. I'd still like to see ITMN do some combo trials perhaps a small investigator trial would be a cheap/low risk way to do this. I believe they mentioned in Germany some are already trying this.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News